Once-Yearly zoledronic acid 5 mg infusion for treatment of postmenopausal osteoporosis: Effects on fracture incidence in patient subgroups from the HORIZON-PFT studyR., EastellD.M., BlackS., BoonenA.R., McLellanS.R., CummingsP.D., Delmas...
Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone ...
Acute and subacute oral toxicity tests of sintered dicalcium pyrophosphate on ovariectomized rats for osteoporosis treatment Sintered dicalcium pyrophosphate (SDCP) is a synthetic pyrophosphate analog that could be utilized in the treatment for osteoporosis. In this study, an ova... KC Yang,CC Wang,CC...
Letter to the Editor: "Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis" A recent study published in the Neurosurgical Review examines the relationship between the recurrence of Rathke's cleft cysts (RCCs) and the position of th......
INTRODUCTION :In women with postmenopausal osteoporosis denosumab discontinuation is associated with rapid bone loss that could be potentially prevented by a single zoledronate infusion for two years. The longer-term effects, however, of zoledronate treatment are unknown. We aimed to study the effect ...
particularly the efficacy of the 5mg annual dose for osteoporosis in breast cancer patients, is limited.#In this 12-month prospective observational study, 85 breast cancer patients were divided into three groups: 17 received no treatment, 17 received tamoxifen, and 51 received anastrozole or letrozol...
BMJ Updates: Yearly infusion of zoledronic acid helps prevent fractures in postmenopausal women with osteoporosisIn this filler item ( BMJ 2007;335:36, 7 Jul, doi: …British Medical Journal Publishing GroupBMJdoi:10.1136/bmj.39316.627014.AD
Infusion of Zoledronic Acid 5mg Versus a Once-Weekly 70-mg Oral Alendronate in the Treatment of Male?Osteoporosis: A Randomized, Multicenter, Double-Blind, Active-Controlled Study Clarke,L B. - 《Yearbook of Medicine》 被引量: 0发表: 2011年 Efficacy and safety of a once-yearly i.v. In...
Methods Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (≤ 3 months) subpopulations]were subgrouped by age; gender; menopausal status in women; dose and ...
Yearly infusion of zoledronic acid helps prevent fractures in postmenopausal women with osteoporosisdoi:10.1136/bmj.39234.488356.DEResearch question Is once yearly intravenous zoledronic acid an effective treatment for postmenopausal osteoporosis? Answer Yes. Yearly treatment prevents fractures and increases ...